Nanolek plans development of vaccine against COVID-19

2 June 2020

The Russian drugmaker Nanolek has started the development of its own vaccine against COVID-19, and has submitted documents for the production of hydroxychloroquine, a medication which is used in Russia to treat coronavirus, according to the company, reports The Pharma Letter’s local correspondent.

An official press spokesman for Nanolek told in an interview with the Russian Forbes magazine that, despite the ongoing development of hundreds of vaccines against CoV2 in the world at present, as part of its plans, the company is developing its own product.

According to Nanolek, currently it is in the process of obtaining an active ingredient, while its vaccine will be based on a recombinant protein molecule. It will be comprised of two parts, the first of which will direct the body's immune response to SARS-CoV2, while the second will strengthen it.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK